NCT07082270 2026-04-15Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple MyelomaRoswell Park Cancer InstitutePhase 1 Withdrawn
NCT06622005 2025-04-16SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaRoswell Park Cancer InstitutePhase 1 Recruiting15 enrolled